Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of sorafenib tosylate in treating patients who have
locally advanced, metastatic, or locally recurrent thyroid cancer. Sorafenib tosylate may
stop the growth of tumor cells by blocking the enzymes necessary for their growth and by
stopping blood flow to the tumor.